10-KPeriod: FY2008

Edwards Lifesciences Corp Annual Report, Year Ended Dec 31, 2008

Filed March 2, 2009For Securities:EW

Summary

Edwards Lifesciences Corporation's 2008 annual report highlights a year of significant growth and strategic developments. The company, a leader in advanced cardiovascular disease technologies, saw its total net sales increase by 13.4% to $1.24 billion. This growth was primarily driven by strong performance in Heart Valve Therapy, particularly with the launch of the Edwards SAPIEN transcatheter heart valve in Europe, and robust sales in Critical Care products like the FloTrac system. Strategically, Edwards Lifesciences continued to focus on its core businesses by divesting the LifeStent product line. The company also made targeted acquisitions, such as CardioVations, to strengthen its minimally invasive surgery portfolio. Significant investments in research and development, especially in transcatheter heart valve technologies, underscore a commitment to future innovation and market leadership. Despite facing a challenging economic environment, the company demonstrated resilience, maintaining a healthy gross profit margin and managing operational expenses effectively.

Financial Highlights

30 data points
Beta

Revenue

$1.24B

66.1% Gross Margin

Net Income

$128.90M

10.4% Net Margin

EPS (Diluted)

$0.18

Cash & Equivalents

$218.70M

Free Cash Flow

$102.60M

Financial Statements
Beta
Revenue$1.24B
Cost of Revenue$419.60M
Gross Profit$818.10M
R&D Expenses$139.20M
SG&A Expenses$480.60M
Interest Expense$7.20M
Net Income$128.90M
EPS (Basic)$0.19
EPS (Diluted)$0.18
Shares Outstanding (Basic)670.20M
Shares Outstanding (Diluted)715.20M

Key Highlights

  • 1Total net sales grew by 13.4% to $1.24 billion in 2008, demonstrating strong top-line performance.
  • 2Heart Valve Therapy sales increased by 17.9%, largely due to the European launch of the Edwards SAPIEN transcatheter heart valve and strong performance of tissue valves.
  • 3Critical Care products saw a 13.6% sales increase, driven by the FloTrac system and other monitoring devices.
  • 4The company divested its LifeStent product line in January 2008, as part of a strategy to focus on core cardiovascular businesses.
  • 5Acquisition of CardioVations in December 2007 bolstered the Cardiac Surgery Systems segment, contributing significantly to its 46.5% sales growth.
  • 6Research and Development expenses increased to $139.2 million (11.2% of net sales), reflecting ongoing investment in innovative technologies, particularly transcatheter heart valves.
  • 7The company ended 2008 with $218.7 million in cash and cash equivalents, maintaining a strong liquidity position.

Frequently Asked Questions

The primary drivers of Edwards Lifesciences' sales growth in 2008 were the strong performance of its Heart Valve Therapy segment, particularly the Edwards SAPIEN transcatheter heart valve launched in Europe, and the Critical Care segment, fueled by the FloTrac system. The acquisition of CardioVations also contributed to the growth in the Cardiac Surgery Systems segment.

The divestiture of the LifeStent product line in January 2008 was a strategic move to focus on core cardiovascular businesses. While this resulted in a $34.6 million write-off of goodwill and an $8.1 million pre-tax loss in the first quarter of 2008, it allowed the company to streamline its portfolio. The company also retained manufacturing for the buyer, generating ongoing revenue.

Edwards Lifesciences views its transcatheter heart valve technology, particularly the Edwards SAPIEN system, as a significant growth area. The company is investing heavily in its development, including ongoing clinical trials like the PARTNER trial for aortic valve replacement and development of systems for mitral valve repair. The company anticipates substantial market opportunity for these less-invasive therapies.

Despite a challenging global economic environment, Edwards Lifesciences demonstrated resilience. The company noted that sales of its products are not generally sensitive to economic conditions, but acknowledged potential risks such as increased customer financial difficulties leading to bad debt or supplier challenges in obtaining credit. However, the company maintained strong sales growth and liquidity throughout the year.